Head-to-head · WeighScore
GoodRx vs Onyx Weight Loss
The verdict
GoodRx takes it — 69.6/100 to 58.8/100.
GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | GoodRx | Onyx Weight Loss |
|---|---|---|
| WeighScore | 69.6/100 | 58.8/100 |
| Grade | C | C |
| Scorecard rank | #116 | #359 |
| Semaglutide | Not disclosed | $228/mo (starting dose, compounded) |
| Tirzepatide | $299/mo (brand Zepbound) | $280/mo (starting dose, compounded) |
| Coverage | All 50 states | 8 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #116 · C
Strengths
- $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
- No membership fee — bring your own prescription and present the discount card at the pharmacy counter
- Brand-name FDA-approved medication, not compounded
Where it loses points
- Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- Self-pay only — does not apply toward insurance benefits or deductibles
- Headline price applies to the lowest Foundayo dose; higher doses may cost more
- No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
- Pricing can change as Lilly's manufacturer coupon program evolves
Graded #359 · C
Strengths
- Competitive entry pricing: semaglutide from $228/mo and tirzepatide from $280/mo with medication + supplies included
- Nurse-practitioner-led care: founder Tasha Vangile FNP-C (20+ years) and Stephanie Robison APRN-CNP (27 years experience)
- Low-cost $99/mo GLP-1 microdosing option for patients who prefer a gradual titration start
- Strive Pharmacy partnership implies compounded 503A-quality supply chain from a known pharmacy
- Multi-modal clinic: GLP-1 + peptides + HRT + nutrition coaching available under one provider team
Where it loses points
- Only 8 states (NC, CO, ME, VT, VA, IA, NH, PA) — excludes the majority of the US
- No LegitScript certification; credentialing evidence limited to local 2025 Best of Iredell award
- Specific drug names (semaglutide/tirzepatide) never stated on website; compounded status inferred, not disclosed
- Labs not included or mentioned; no baseline bloodwork protocol published
- Pricing shown as 'Starting at' with no dose-escalation tier pricing disclosed publicly
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.